KSPHF:OTCMKTS
Kissei Pharmaceutical Co Ltd
24,50 US$
0,00%
(0,00) 1D
1. okt., 09.21.43 GMT-5 · USD
search
Alle symboler
| Symbol | Pris | Ændring | Ændring i % |
|---|
insights_autoGenererer vigtig indsigt for KSPHF...
Markedsværdi
180,82 mia.
Gns. vol.
20,00
Volumen
0,00
Højeste i 52 uger
31,90 US$
Laveste i 52 uger
24,50 US$
Beta
13,94
Aktier i omløb
46,54 mio.
Antal ansatte
2 t
Markedsværdi
180,82 mia.
Gns. vol.
20,00
Volumen
0,00
Højeste i 52 uger
31,90 US$
Laveste i 52 uger
24,50 US$
Beta
13,94
Aktier i omløb
46,54 mio.
Antal ansatte
2 t
Nyhedshistorier
Fra webkilder og nyhedspartnere
BigGo Finance
·
for 4 timer siden
Goldman Sachs Sets 8,700 S&P 500 Target for 2027, Sees 14% Upside as AI Capex Peaks
The Motley Fool
·
for 3 timer siden
Tesla Is Down 13% in 2026 While the S&P 500 Is Up. Here’s the 1 Catalyst Left This Year That Could Flip That.
24/7 Wall St.
·
for 2 timer siden
Gilead Beat the S&P 500 by More Than 25 Points in the Past Year, but $1,000 From a Decade Ago Is Still Worth Less Than $3,500
Traders Union
·
for 1 time siden
Chris Ciovacco: Semiconductors SMH and S&P 500 SPY show several possible support areas
Profil
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
Om Kissei Pharmaceutical Co Ltd
Administrerende direktørMutsuo Kanzawa
Ansatte1,79 t
Grundlagt9. aug. 1946
HovedsædeMatsumoto, Nagano, Japan
SektorHealth Care
Branche-
Websitekissei.co.jp